Charlie Bachtell, CEO of Cresco Labs and Chair of US Cannabis Roundtable:
“The US Cannabis Roundtable commends President Trump and the Trump Administration for moving to reclassify cannabis as a Schedule III drug. Once completed, this shift will mark a dramatic break with the failed policies of the past.
“Cannabis has widely accepted medical uses and low abuse potential. It never belonged at Schedule I. After more than five decades, this untenable status quo is finally coming to an end.”
Saphira Galoob, CEO of US Cannabis Roundtable:
“President Trump first endorsed reclassifying cannabis in September of 2024, citing a desire for more research to unlock medical uses of cannabis. Now he is delivering. The shift underway is smart policy, backed by science, and overwhelmingly popular.”
Kim Rivers, CEO of Trulieve and Vice Chair of US Cannabis Roundtable:
“Thank you President Trump. By any measure, you are on track to deliver the single greatest cannabis reform in US history. Your resolute action will generate far-reaching benefits for years to come.”